12:00 AM
 | 
May 24, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CMA 676: Phase II/III

The initial 59 patients treated in CTP's pivotal Phase II/III trial had a 36 percent remission rate and complete clearance of clinically evident leukemic...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >